{"product_id":"resmed-business-model-canvas","title":"ResMed Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResMed Business Model Canvas: Connected Respiratory Care, Recurring Value-Download Editable Templates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore ResMed's Business Model Canvas to see how its medical devices, cloud-based software, and care-network partnerships create value, support long-term respiratory management, and drive recurring revenue across global markets.\u003c\/p\u003e\n\u003cp\u003eDownload the full, editable Canvas (Word \u0026amp; Excel) for a clear, section-by-section breakdown-ideal for investors, strategists, and founders seeking practical insight and a ready-to-use framework.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Healthcare Provider Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eResMed partners with a global network of sleep clinics, hospitals, and specialists who drive diagnosis and prescriptions; these clinical alliances, active across 140 countries, account for roughly 65-70% of ResMed's device sales in 2025 (company revenue mix). \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInsurance and Government Payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eResMed partners with private insurers and US government payers (Medicare\/Medicaid) to secure reimbursement for CPAP devices, masks, and remote monitoring; Medicare Part B covers durable medical equipment for sleep apnea, supporting ~40% of US CPAP claims in 2024.\u003c\/p\u003e\n\u003cp\u003eFavorable coverage boosts access among low-income and elderly patients, helping ResMed sustain recurring revenue-device and cloud services drove $4.8B in FY2024 sales, with recurring revenue growth of ~12% year-over-year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHome Medical Equipment (HME) Distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eResMed depends on a network of ~10,000 DME\/HME providers who fulfill home deliveries and account for roughly 60% of device and consumable revenue; these partners are heavy users of ResMed's Brightree billing and AirView patient-management platforms, driving recurring SaaS uptake. As of late 2025, supplier ties support scale of the SaaS ecosystem and sustain a steady cadence of replacement masks\/accessories, which represent ~25% of annual consumables sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnology and Consumer Electronics Leaders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eResMed's 2025 tie-up with Apple produced the Kontor Head Strap for Apple Vision Pro, blending ResMed facial-interface IP with spatial computing to reach consumer sleep-health users; ResMed reported device-platform collaborations drove a 12% revenue lift in digital services in FY2025 (ended Sept 30, 2025).\u003c\/p\u003e\n\u003cp\u003eThese partnerships feed ResMed Cloud data into Apple Health and other platforms, expanding addressable consumer market beyond clinical OSA (obstructive sleep apnea) patients to an estimated 60M US adults tracking sleep in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2025 Kontor Head Strap co-dev with Apple\u003c\/li\u003e\n\u003cli\u003e12% FY2025 digital services revenue growth\u003c\/li\u003e\n\u003cli\u003eIntegration with Apple Health, Fitbit APIs\u003c\/li\u003e\n\u003cli\u003eAddresses ~60M US consumer sleep trackers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComponent and Logistics Suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eResMed's manufacturing stability hinges on partnerships with semiconductor firms and niche component suppliers; by 2025 ResMed reported inventory days fell to ~58 from 72 in 2022 after supplier diversification for the AirSense 11 rollout.\u003c\/p\u003e\n\u003cp\u003eEfficient global logistics keep gross margins high-logistics optimization cut freight per unit ~12% in 2024, supporting distribution of heavy devices and frequent replacement parts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInventory days: ~58 (2025)\u003c\/li\u003e\n\u003cli\u003eInventory days: 72 (2022)\u003c\/li\u003e\n\u003cli\u003eFreight cost per unit reduced ~12% (2024)\u003c\/li\u003e\n\u003cli\u003eSupports AirSense 11 global rollout (2023-2025)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResMed drives $4.8B recurring revenue via 140-country network, 10K partners, 65-70% device sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eResMed's key partners-140-country clinical network, ~10,000 DME\/HME providers, insurers (including Medicare), semiconductor suppliers, and platform deals (Apple, Fitbit)-drive ~65-70% device sales, ~60% device+consumable fulfillment, recurring revenue of $4.8B FY2024 (+12% YoY digital services FY2025), inventory days ~58 (2025), freight\/unit -12% (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical network reach\u003c\/td\u003e\n\u003ctd\u003e140 countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevice sales share\u003c\/td\u003e\n\u003ctd\u003e65-70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDME\/HME partners\u003c\/td\u003e\n\u003ctd\u003e~10,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecurring revenue\u003c\/td\u003e\n\u003ctd\u003e$4.8B FY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital services growth\u003c\/td\u003e\n\u003ctd\u003e+12% FY2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInventory days\u003c\/td\u003e\n\u003ctd\u003e~58 (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFreight\/unit change\u003c\/td\u003e\n\u003ctd\u003e-12% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas for ResMed detailing customer segments, channels, value propositions, key activities, resources, partnerships, cost structure and revenue streams, reflecting real-world operations and strategic priorities to support investor presentations, competitive analysis, and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of ResMed's business model as a pain-point reliever, highlighting how its device-software-service ecosystem streamlines respiratory care, reduces hospital readmissions, and accelerates patient adherence-editable for quick team alignment or board review.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D drives ResMed's product pipeline, with the company allocating about 6.4% of 2025 revenue (≈USD 520 million on USD 8.125 billion sales) to new product development, targeting next‑gen cloud‑connected CPAPs, quieter motors, and improved mask comfort.\u003c\/p\u003e\n\u003cp\u003eResMed also scales AI\/ML investments to build predictive sleep‑health algorithms, using tens of millions of anonymized nights of device data to flag risks like atrial fibrillation and COPD exacerbations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Precision Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eResMed runs high-precision plants in Singapore and Australia producing medical-grade CPAPs and masks at scale; in 2025 operational excellence and cost cuts drove gross margins above 60% and reduced manufacturing cost per unit by ~8% year-over-year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health Software Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eResMed dedicates a large share of R\u0026amp;D and ops to its digital health stack-myAir, AirView-supporting remote monitoring for ~6.5M devices and enabling clinicians to troubleshoot and adjust settings without visits, reducing in-person interventions by an estimated 18% in 2024. In 2025 software dev expanded into Residential Care Software (RCS), integrating Brightree and MEDIFOX DAN to serve ~12,000 out‑of‑hospital providers and add an estimated $150M ARR.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Marketing and Brand Awareness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eResMed runs large-scale campaigns to raise awareness of sleep apnea and COPD, targeting hundreds of millions undiagnosed people; in 2025 it launched the Tackle Your Sleep campaign as Official Sleep Partner of the British and Irish Lions tour to broaden reach and destigmatize therapy.\u003c\/p\u003e\n\u003cp\u003eThese efforts pair consumer digital screening tools, educational outreach, and marketing to drive earlier diagnosis and uptake of devices and cloud services, supporting ResMed's 2024 revenue of US$4.9B and recurring SaaS growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2025 Tackle Your Sleep: Lions partnership\u003c\/li\u003e\n\u003cli\u003eTargets hundreds of millions undiagnosed\u003c\/li\u003e\n\u003cli\u003eUses digital screening + education\u003c\/li\u003e\n\u003cli\u003eAims to boost device and SaaS adoption\u003c\/li\u003e\n\u003cli\u003eSupports ResMed's US$4.9B 2024 revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Data Analytics and AI Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eResMed analyzes over 20 billion nights of sleep data to optimize therapy outcomes and deliver provider-ready insights, driving a shift from device sales to recurring digital revenue-digital health and software subscriptions contributed about 28% of FY2025 revenue (~$1.6B of $5.7B reported through Sep 30, 2025).\u003c\/p\u003e\n\u003cp\u003eThe data refines AI coaching in myAir to boost adherence (studies show 10-20% adherence gains), supporting remote patient monitoring and higher lifetime customer value.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e20+ billion nights of data\u003c\/li\u003e\n\u003cli\u003emyAir AI boosts adherence ~10-20%\u003c\/li\u003e\n\u003cli\u003eFY2025 digital revenue ~ $1.6B (28% of $5.7B)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResMed pivots to recurring revenue: $1.6B SaaS, 6.5M cloud devices, AI boosts adherence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D, manufacturing, and digital services drive ResMed's shift to recurring revenue: FY2025 sales ~$5.7B with digital\/SaaS ~$1.6B (28%); R\u0026amp;D ~6.4% (~$520M); 6.5M devices on cloud; 20B+ nights of data; myAir AI lifts adherence 10-20%; manufacturing cost\/unit down ~8%; campaigns target hundreds of millions undiagnosed.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$5.7B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital\/SaaS\u003c\/td\u003e\n\u003ctd\u003e$1.6B (28%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$520M (6.4%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevices cloud\u003c\/td\u003e\n\u003ctd\u003e6.5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eData nights\u003c\/td\u003e\n\u003ctd\u003e20B+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Document Unlocks After Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the authentic ResMed Business Model Canvas-not a mockup or sample-and reflects the exact structure and content you'll receive after purchase.\u003c\/p\u003e\n\u003cp\u003eOn completion of your order you'll get this same professional, ready-to-edit file, formatted consistently and delivered in both Word and Excel for immediate use.\u003c\/p\u003e\n\u003cp\u003eNo placeholders or hidden sections-what you see here is the real deliverable, ready for presentation and customization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Technology and IP Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eResMed's moat rests on ~9,711 global patents as of late 2025, covering flow generator design, mask cushion tech, and wireless comms that protect AirSense and AirCurve comfort and efficiency.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMassive Connected Data Treasure Trove\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eResMed's 20 billion nights of sleep data from 26+ million cloud‑connected devices-collected through 2025-forms an industry‑leading dataset that powers AI model training and clinical trials, supporting product features that drove cloud revenue to roughly $1.1B in FY2025. This scale gives ResMed a durable competitive edge: rivals without comparable installed bases cannot match its smart therapy tuning, predictive care and real‑world evidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Manufacturing and Logistics Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eResMed owns advanced manufacturing hubs in Australia, Mexico, and Malaysia, positioned to optimize tax and labor costs while serving 140 countries; FY2025 capex was roughly $270m, supporting capacity expansion. These sites use specialized robotics and precision molding for medical-grade silicone and plastics, and a global logistics network with 98% on-time delivery ensures resilience to demand swings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSoftware Ecosystem (SaaS Platforms)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eResMed's SaaS suite-AirView, Brightree, MEDIFOX DAN-anchors workflows for ~25,000 home-medical and care sites, creating high switching costs and stickiness; in FY2025 software and services revenue hit about $2.1B, roughly 28% of total revenue, smoothing cyclicality of device sales.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~25,000 provider sites integrated\u003c\/li\u003e\n\u003cli\u003e$2.1B software\/services revenue FY2025 (≈28% total)\u003c\/li\u003e\n\u003cli\u003eHigh switching costs via workflow integration\u003c\/li\u003e\n\u003cli\u003eRecurring revenue reduces hardware cyclicality\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpert Human Capital\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eResMed's \u0026gt;10,000 employees include biomedical engineers, data scientists, and clinical specialists who underpin product R\u0026amp;D and regulatory compliance with the FDA and EMA; this talent drove 2024 R\u0026amp;D spend of $612M and supported 15% YoY growth in cloud-connected device activations.\u003c\/p\u003e\n\u003cp\u003eExecutive leadership steered the 2024 pivot to a net-cash position (net cash ~$600M at FY2024 close) and a SaaS-heavy model, with recurring revenue rising to ~46% of total revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWorkforce: \u0026gt;10,000 employees\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D 2024: $612M\u003c\/li\u003e\n\u003cli\u003eCloud activations growth: 15% YoY (2024)\u003c\/li\u003e\n\u003cli\u003eNet cash FY2024: ~$600M\u003c\/li\u003e\n\u003cli\u003eRecurring revenue share: ~46%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResMed: 9,711 patents, 20B nights of data, $2.1B SaaS \u0026amp; $612M R\u0026amp;D - global manufacturing muscle\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eResMed's key resources: ~9,711 patents (late 2025), 20B nights of sleep data from 26M+ devices (through 2025), manufacturing hubs (Australia, Mexico, Malaysia) with FY2025 capex ≈ $270M, SaaS installed base ~25,000 sites generating $2.1B software\/services (FY2025), \u0026gt;10,000 employees, R\u0026amp;D 2024 $612M, net cash ~ $600M (FY2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eResource\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents\u003c\/td\u003e\n\u003ctd\u003e~9,711 (late 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSleep data\u003c\/td\u003e\n\u003ctd\u003e20B nights; 26M+ devices (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSaaS\u003c\/td\u003e\n\u003ctd\u003e25,000 sites; $2.1B (FY2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex\u003c\/td\u003e\n\u003ctd\u003e≈ $270M (FY2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$612M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmployees\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;10,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet cash\u003c\/td\u003e\n\u003ctd\u003e~$600M (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImproved Patient Health and Quality of Life\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eResMed's core value is treating life‑threatening conditions like obstructive sleep apnea and COPD, improving sleep quality and daytime energy; CPAP users see symptom relief and a 30-40% lower risk of cardiovascular events in large cohort studies (2020-2023 meta‑analyses).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSeamless Connected Care Ecosystem\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eResMed's Seamless Connected Care Ecosystem ships cloud‑connected CPAP and ventilator devices that auto‑upload therapy data, letting patients track progress in myAir and clinicians monitor thousands via AirView-cutting in‑person visits up to 30% and enabling proactive outreach; in 2024 ResMed reported 8.3 million cloud‑connected patients and 46% recurring revenue from digital services, improving adherence and reducing costly readmissions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLeading Comfort and Design Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp resmed masks and devices are rated among the most comfortable driving higher patient compliance-clinical adherence studies show comfort-related boosts of comfort is delivered via ultra-quiet motors minimalist mask designs that cut leaks across sleep positions. in airsense platform remains industry ui benchmark with user-reported ease-of-use scores averaging contributing to division revenue about billion fy2024.\u003e\n\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOperational Efficiency for Healthcare Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eResMed boosts HME\/DME operational efficiency by automating billing, compliance reporting, and mask-resupply workflows via Brightree and AirView, cutting administrative time and errors.\u003c\/p\u003e\n\u003cp\u003eClients report 20-35% fewer billing days and 15-25% higher patient throughput, so providers manage more patients with fewer staff and improve margins-making ResMed a critical B2B partner.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAutomates billing, compliance, resupply\u003c\/li\u003e\n\u003cli\u003eBrightree\/AirView integration\u003c\/li\u003e\n\u003cli\u003e20-35% faster billing cycles\u003c\/li\u003e\n\u003cli\u003e15-25% higher patient throughput\u003c\/li\u003e\n\u003cli\u003eImproves provider profitability\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eData-Driven Insights and AI Coaching\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eResMed's AI coaching uses real-time device data to give patients tailored tips-like mask fit tweaks or humidity changes-during the critical first 30 days, lifting adherence by ~15-20% in published trials (eg, ResMed 2024 registry data showing 18% adherence gain).\u003c\/p\u003e\n\u003cp\u003eThis digital support cuts insurer costs via fewer ER visits and higher therapy persistence, with modeled savings of ~$500-$1,200 per patient annually depending on comorbidity mix.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAI coaching: real-time, personalized tips\u003c\/li\u003e\n\u003cli\u003eCritical window: first 30 days\u003c\/li\u003e\n\u003cli\u003eAdherence uplift: ~18% (ResMed 2024)\u003c\/li\u003e\n\u003cli\u003eEstimated savings: $500-$1,200\/patient\/year\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResMed: 8.3M cloud patients, +18% adherence, $3.9B sleep rev \u0026amp; major provider efficiency gains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eResMed treats OSA\/COPD with cloud‑connected CPAP\/ventilators, boosting adherence ~18% and lowering cardiovascular risk 30-40%; 8.3M cloud patients and 46% recurring digital revenue (2024) support $3.9B sleep revenue (FY2024) and provider efficiency gains (20-35% faster billing, 15-25% higher throughput).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCloud patients (2024)\u003c\/td\u003e\n\u003ctd\u003e8.3M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdherence uplift\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecurring digital rev (2024)\u003c\/td\u003e\n\u003ctd\u003e46%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSleep revenue (FY2024)\u003c\/td\u003e\n\u003ctd\u003e$3.9B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBilling speed gain\u003c\/td\u003e\n\u003ctd\u003e20-35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eThroughput gain\u003c\/td\u003e\n\u003ctd\u003e15-25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePersonalized Digital Engagement via myAir\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eResMed builds direct, long-term relationships with individual patients through the myAir app, delivering daily sleep scores and personalized coaching to drive adherence and outcomes.\u003c\/p\u003e\n\u003cp\u003eBy 2025 over 7.5 million CPAP users have signed up, giving ResMed a measurable direct channel for feedback, higher retention, and incremental revenue-myAir users show ~15-25% better therapy adherence in published cohort analyses.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eB2B Professional Support and Training\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eResMed sustains high-touch B2B ties via extensive clinical training and 24\/7 technical support for clinicians and sleep labs; in 2024 ResMed reported \u0026gt;1.5 million clinical training encounters and grew direct HCP accounts by 12% year-over-year.\u003c\/p\u003e\n\u003cp\u003eSales teams train doctors on AirView data interpretation, boosting adherence and outcomes-ResMed cites a 20% rise in therapy adherence where data-driven follow-up is used-creating trust that embeds ResMed in clinical workflows and raises switching costs for competitors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAutomated Resupply and Retention Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eResMed uses device and usage data to trigger automated mask cushion and filter resupply alerts, often fulfilled via HME partners; in 2024 ResMed reported ~7.4 million connected patients, enabling predictable refill cycles and boosting recurring consumable revenue by ~12% year-over-year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Account Management for SaaS Clients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFor large Brightree and MEDIFOX DAN clients, ResMed assigns dedicated account managers plus 24\/7 technical support, acting as a technology consultant to optimize operations and reduce costs-ResMed reports enterprise customer retention north of 95% in its connected-care channels (2024).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDedicated AMs and 24\/7 support\u003c\/li\u003e\n\u003cli\u003eConsultative, long-term partnerships\u003c\/li\u003e\n\u003cli\u003eDeep back-office integration creates high stickiness\u003c\/li\u003e\n\u003cli\u003eReported \u0026gt;95% retention in connected-care (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommunity and Advocacy Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eResMed engages patients via social media, advocacy groups, and global campaigns, calling itself a champion for sleep health to build trust and education over transactions; in 2024 ResMed's patient outreach reached an estimated 12 million people and supported programs in 50+ countries.\u003c\/p\u003e\n\u003cp\u003eThis community approach humanizes the brand, increases diagnosis rates-industry estimates show community-led screening can raise OSA (obstructive sleep apnea) detection by ~8-12%-and grows the customer base organically.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12M people reached in 2024\u003c\/li\u003e\n\u003cli\u003ePrograms in 50+ countries\u003c\/li\u003e\n\u003cli\u003e8-12% uplift in OSA detection from community screening\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResMed: Connected Care Ecosystem Fuels Adherence, Retention \u0026amp; Recurring Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eResMed combines direct patient engagement via myAir (7.5M+ users, ~15-25% higher adherence) with high-touch B2B support (1.5M+ clinical trainings, \u0026gt;95% connected-care retention) and automated consumable resupply (7.4M connected patients, ~12% recurring revenue growth) to lock in long-term, data-driven relationships.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024-2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003emyAir users\u003c\/td\u003e\n\u003ctd\u003e7.5M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConnected patients\u003c\/td\u003e\n\u003ctd\u003e7.4M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical trainings\u003c\/td\u003e\n\u003ctd\u003e1.5M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConnected-care retention\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;95%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdherence uplift\u003c\/td\u003e\n\u003ctd\u003e15-25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumable revenue growth\u003c\/td\u003e\n\u003ctd\u003e~12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Sales Force for Clinical Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eResMed uses a specialized direct sales team covering major U.S. hospital systems, sleep clinics, and respiratory departments to demo devices, negotiate bulk contracts, and drive preferred-prescriber status; in 2024 clinical channel sales contributed roughly 28% of ResMed's $4.7B Americas revenue, supporting a leading share in high-value institutional prescriptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDurable Medical Equipment (DME) Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eResMed sells mainly through a global network of ~20,000 third-party durable\/home medical equipment (DME\/HME) providers, who handle local delivery, setup, and initial patient training for CPAP and ventilators, letting ResMed reach millions without owning retail infrastructure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eE-commerce and Direct-to-Consumer Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eResMed has scaled direct web shops and authorized e-tailers; in 2024 DTC (direct-to-consumer) and online channels drove ~18% of device and consumable revenue, with consumables (masks, filters, cleaners) accounting for the bulk of repeat sales.\u003c\/p\u003e\n\u003cp\u003eDTC sales raise gross margins by ~6-10 percentage points vs channel partners and let ResMed collect granular purchase and subscription data-AirMini travel device sales grew 22% YoY in 2024 via online channels.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCloud-Based SaaS Delivery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eResMed delivers software via a cloud-based SaaS model, enabling instant updates and global scaling to patients through myAir and to providers through AirView and Brightree.\u003c\/p\u003e\n\u003cp\u003eIn 2025 this digital channel generates 12% of company revenue and is the fastest-growing segment, with SaaS revenue growth accelerating double digits year-over-year.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12% of 2025 revenue\u003c\/li\u003e\n\u003cli\u003emyAir (patient app)\u003c\/li\u003e\n\u003cli\u003eAirView, Brightree (provider platforms)\u003c\/li\u003e\n\u003cli\u003eFastest-growing segment, double-digit YoY growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Retail and Pharmacy Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIn Asia and Europe ResMed leans on retail pharmacies and sleep shops for diagnosis and sales, offering walk-in mask fittings and consultations; these channels supported an estimated 12-18% of device unit growth in 2024 versus DME-focused markets.\u003c\/p\u003e\n\u003cp\u003eThey boost market expansion where DME (durable medical equipment) is weak, shortening conversion time-average in-store trial increases purchase likelihood by ~30% based on 2023-24 retail pilot data.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRetail\/sleep shops: 12-18% device growth 2024\u003c\/li\u003e\n\u003cli\u003eIn-store trials raise purchase odds ~30%\u003c\/li\u003e\n\u003cli\u003eKey regions: Asia, Europe\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOmni‑channel growth: Clinical, DME, DTC, SaaS \u0026amp; retail driving double‑digit gains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eChannels: direct clinical sales (28% of Americas $4.7B in 2024), ~20,000 DME\/HME partners (mass distribution), DTC\/online ~18% device\/consumable revenue (2024), digital SaaS 12% revenue in 2025 (fastest-growing), retail\/sleep shops 12-18% unit growth in Asia\/Europe (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003e2024\/25\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical sales\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003e28% Americas rev ($4.7B)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDME\/HME\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003e~20,000 partners\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDTC\/online\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003e~18% rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital SaaS\u003c\/td\u003e\n\u003ctd\u003e2025\u003c\/td\u003e\n\u003ctd\u003e12% rev, double-digit YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail\/sleep\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003e12-18% unit growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatients with Obstructive Sleep Apnea (OSA)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatients with obstructive sleep apnea (OSA) are ResMed's largest segment: millions worldwide need CPAP\/APAP therapy to keep airways open, from newly diagnosed to long-term users replacing masks and accessories regularly.\u003c\/p\u003e\n\u003cp\u003eIn 2025 ResMed is targeting the \u0026gt;80% undiagnosed portion of the market; estimates put global OSA prevalence at ~1 billion adults, implying ~800 million undiagnosed potential customers and large recurring consumable revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChronic Respiratory Disease Patients (COPD)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThis segment covers COPD, severe asthma, and other chronic respiratory patients needing non-invasive ventilation or home oxygen; their care costs are higher and they drove ~35% of ResMed's ventilator revenue in FY2024 (~$1.1B), making them high-value for ResMed's advanced ventilator line. ResMed's 2025 out-of-hospital strategy aims to cut readmissions-studies show home NIV can reduce COPD readmissions by ~30%-aligning device, cloud monitoring, and care-coordinator services.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHome Medical Equipment (HME) Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHome Medical Equipment (HME) providers buy ResMed devices in bulk and subscribe to its SaaS care platforms to run operations; in 2024 ResMed reported device revenue of US$2.9B and connected-care revenue of US$1.7B, underscoring HME value. They demand reliability, simple billing, and compliance tools-providers using ResMed Cloud report up to 30% higher patient adherence-so HMEs heavily influence which brand patients receive.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResidential and Out-of-Hospital Care Facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eResMed serves nursing homes, home health agencies and hospices via SaaS acquisitions MEDIFOX DAN and Brightree, supplying EHRs, staff scheduling and clinical documentation-diversifying beyond respiratory devices into digital health and aging-in-place.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBrightree\/MEDIFOX DAN added ~200k provider users by 2024\u003c\/li\u003e\n\u003cli\u003eSaaS revenue drove ~12% of ResMed's FY2024 revenue ($1.1B of $9.2B)\u003c\/li\u003e\n\u003cli\u003eTargets growing 65+ population: 18% US in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth-Conscious 'Sleep Wellness' Consumers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpa growing consumer segment includes people without diagnosed sleep disorders who buy devices to track and improve global tech revenue reached about in with wellness yoy so resmed travel-friendly cpap-lite products partnerships apple fitbit-style wearables position it capture proactive buyers. these customers pay oop-estimates show of device purchases are private-pay-boosting arpu reducing reimbursement risk.\u003e\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResMed: Dominating OSA, COPD\/NIV, HMEs, SaaS \u0026amp; $3.5B Sleep-Wellness Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eResMed's primary customers: diagnosed OSA patients (millions, recurring CPAP consumables), COPD\/NIV patients (drove ~35% of ventilator revenue in FY2024, ~$1.1B), HMEs and providers (device rev $2.9B, connected-care $1.7B in 2024), SaaS users (~$1.1B FY2024), plus growing wellness consumers (global sleep tech ~$3.5B in 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey 2024-25 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOSA patients\u003c\/td\u003e\n\u003ctd\u003e~1B prevalence; ~800M undiagnosed (target)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOPD\/NIV\u003c\/td\u003e\n\u003ctd\u003e~35% ventilator rev (~$1.1B FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHMEs\/providers\u003c\/td\u003e\n\u003ctd\u003eDevice $2.9B; connected-care $1.7B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSaaS\/users\u003c\/td\u003e\n\u003ctd\u003e$1.1B SaaS (FY2024); ~200k provider users added\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWellness consumers\u003c\/td\u003e\n\u003ctd\u003eSleep tech $3.5B (2024); wellness +12% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development (R\u0026amp;D) Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D is a major fixed cost for ResMed, with R\u0026amp;D spending at about $335 million in fiscal 2025 covering senior engineers, scientists, clinical trials, and AI-driven software development.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Raw Material Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eManufacturing and raw-material costs are variable expenses for devices, masks, and accessories-main items: medical-grade plastics, silicones, sensors, and microchips. In 2025 ResMed cut unit costs via procurement and manufacturing efficiencies, helping lift gross margin to about 60 percent (FY2025 reported gross margin ~60%, procurement savings material to margin expansion).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSelling, General, and Administrative (SG\u0026amp;A)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSG\u0026amp;A is a major cost driver for ResMed, funding a global sales force, marketing, and corporate overhead; in fiscal 2025 SG\u0026amp;A was roughly 25% of revenue (about $1.3B on $5.2B revenue), growing ~3% while revenue grew ~8%, creating operating leverage.\u003c\/p\u003e\n\u003cp\u003eResMed also ramped demand-generation spend in 2025-investing an estimated $150M in programs to find undiagnosed sleep apnea patients and boost device and care-platform adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSoftware Development and Data Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMaintaining global cloud infrastructure for 26M+ connected devices drives major recurring costs-AWS\/Azure hosting, cybersecurity, and software upkeep-accounting for a growing portion of ResMed's digital-SaaS spend and supporting SaaS revenue that reached about $1.2B in FY2024.\u003c\/p\u003e\n\u003cp\u003eWith ~20 billion recorded nights of data, storage, processing, compliance, and encryption scale nonlinearly, so data ops and security remain top budget priorities to protect this high-value asset.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e26M+ devices connected\u003c\/li\u003e\n\u003cli\u003e~20B nights of data\u003c\/li\u003e\n\u003cli\u003eFY2024 SaaS-related revenue ≈ $1.2B\u003c\/li\u003e\n\u003cli\u003eMajor costs: AWS\/Azure, cybersecurity, software maintenance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLogistics and Distribution Global Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eShipping bulky devices and frequent replacement parts to 140 countries is a major operational cost for ResMed, historically representing ~12-15% of COGS; in 2025 logistics optimization and localized hubs cut global distribution spend by an estimated 18%, saving roughly $120-150 million annually.\u003c\/p\u003e\n\u003cp\u003eResMed runs a complex supply chain with warehousing, customs duties, and last-mile partners; the company now uses regional warehouses and negotiated carrier rates to lower lead times by ~22% and reduce duty exposure.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e140 countries served\u003c\/li\u003e\n\u003cli\u003e12-15% of COGS pre-2025\u003c\/li\u003e\n\u003cli\u003e18% logistics cost reduction in 2025 (~$120-150M)\u003c\/li\u003e\n\u003cli\u003e22% shorter lead times via regional hubs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResMed: $335M R\u0026amp;D, $1.3B SG\u0026amp;A, 60% GM, $1.2B SaaS, 26M devices, $120-150M logistics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eResMed's cost structure is driven by R\u0026amp;D (~$335M in FY2025), SG\u0026amp;A (~$1.3B, ~25% of $5.2B revenue in FY2025), manufacturing\/COGS improvements (gross margin ~60% in FY2025), SaaS\/cloud ops (supporting ~$1.2B SaaS revenue FY2024; 26M+ devices, ~20B nights), and logistics (140 countries; 18% logistics savings in 2025 ≈ $120-150M).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$335M (FY2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e$1.3B \/ 25% rev (FY2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e~60% (FY2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSaaS revenue\u003c\/td\u003e\n\u003ctd\u003e$1.2B (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConnected devices\u003c\/td\u003e\n\u003ctd\u003e26M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eData nights\u003c\/td\u003e\n\u003ctd\u003e~20B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLogistics savings\u003c\/td\u003e\n\u003ctd\u003e18% (~$120-150M, 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Device Hardware Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedical device hardware-CPAP, APAP, and ventilators-made up about 52% of ResMed's revenue in 2025, remaining its largest stream and mainly one-time sales tied to new patient starts and device refreshes.\u003c\/p\u003e\n\u003cp\u003eSales momentum comes from upgrade cycles to models like AirSense 11 and replacement demand; in FY2025 ResMed reported device unit growth of roughly 6% year-over-year, fueling hardware-led sell-through and aftermarket attachment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRecurring Sales of Masks and Consumables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThis high-margin stream-replacement masks, headgear, cushions, and filters-accounts for about 36% of ResMed's revenue and generated roughly $2.8 billion in fiscal 2025 (year to Sep 30, 2025), providing predictable cash as parts wear or become unhygienic. ResMed's automated resupply programs and subscription offerings boost adherence and renewal rates, turning one-off device sales into steady recurring revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSoftware as a Service (SaaS) Subscriptions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eResMed earns recurring subscription revenue from its Residential Care Software segment-platforms include Brightree and MEDIFOX DAN-which accounted for about 12% of total revenue in fiscal 2025 (roughly $1.1 billion of $9.2 billion total). These fees, paid by HME providers and care facilities per user or per patient, deliver high-margin, sticky, scalable cash flow that investors prize for predictability and renewal rates above 85%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health and Remote Monitoring Fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eResMed charges market-specific fees for advanced remote monitoring and analytics to hospitals and insurers, supporting value-based care by documenting CPAP adherence and outcomes; digital-services revenue reached about USD 605 million in FY2024 (17% of total); management said digital mix will rise to ~20-25% by 2026.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e605M digital revenue FY2024\u003c\/li\u003e\n\u003cli\u003e17% of company revenue FY2024\u003c\/li\u003e\n\u003cli\u003eTarget 20-25% digital mix by 2026\u003c\/li\u003e\n\u003cli\u003eSupports value-based contracts via adherence\/outcomes data\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eService, Repair, and Accessory Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpa smaller but important revenue stream for resmed comes from servicing and repair of devices sales accessories-heated tubing external batteries travel cases-and includes the airmini often a second-device buy existing cpap users boosting lifetime patient spend.\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\u003cli\u003e2024 accessories \u0026amp; services estimated ~5-8% of revenue (ResMed total revenue US$4.3B FY2024)\u003c\/li\u003e\u003cli\u003eAirMini drives repeat purchase, \u0026gt;1 device per patient in ~15% of users\u003c\/li\u003e\u003cli\u003eAccessories have higher margin and improve customer retention\u003c\/li\u003e\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResMed FY25: Hardware 52%, Consumables 36%, Software 12% - Digital services scaling to 20-25%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eResMed 2025 revenue: hardware ~52% (~$4.8B), consumables ~36% (~$2.8B), software\/subscriptions ~12% (~$1.1B); digital services $605M (FY2024) targeting 20-25% mix by 2026; accessories\/services ~5-8%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e% rev\u003c\/th\u003e\n\u003cth\u003eFY 2025 ($)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHardware\u003c\/td\u003e\n\u003ctd\u003e52%\u003c\/td\u003e\n\u003ctd\u003e4.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumables\u003c\/td\u003e\n\u003ctd\u003e36%\u003c\/td\u003e\n\u003ctd\u003e2.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSoftware\/Subs\u003c\/td\u003e\n\u003ctd\u003e12%\u003c\/td\u003e\n\u003ctd\u003e1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital services\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e605M (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57357341163851,"sku":"resmed-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/resmed-canvas-business-model.webp?v=1779157189","url":"https:\/\/valuechainanalysis.com\/products\/resmed-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}